KR102328028B1 - Jelly type composition for enhancing concentration - Google Patents
Jelly type composition for enhancing concentration Download PDFInfo
- Publication number
- KR102328028B1 KR102328028B1 KR1020210086590A KR20210086590A KR102328028B1 KR 102328028 B1 KR102328028 B1 KR 102328028B1 KR 1020210086590 A KR1020210086590 A KR 1020210086590A KR 20210086590 A KR20210086590 A KR 20210086590A KR 102328028 B1 KR102328028 B1 KR 102328028B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- present
- jelly
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 235000015110 jellies Nutrition 0.000 title abstract description 34
- 239000008274 jelly Substances 0.000 title abstract description 29
- 230000002708 enhancing effect Effects 0.000 title description 3
- 239000000284 extract Substances 0.000 claims abstract description 34
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 43
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 37
- 235000020733 paullinia cupana extract Nutrition 0.000 claims description 26
- 235000014826 Mangifera indica Nutrition 0.000 claims description 25
- 241001093152 Mangifera Species 0.000 claims description 24
- 235000004936 Bromus mango Nutrition 0.000 claims description 23
- 235000009184 Spondias indica Nutrition 0.000 claims description 23
- 229940026510 theanine Drugs 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 229960003080 taurine Drugs 0.000 claims description 18
- 229930064664 L-arginine Natural products 0.000 claims description 17
- 235000014852 L-arginine Nutrition 0.000 claims description 17
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 16
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 16
- 244000078534 Vaccinium myrtillus Species 0.000 claims description 16
- 235000000556 Paullinia cupana Nutrition 0.000 claims description 14
- 240000003444 Paullinia cupana Species 0.000 claims description 14
- 235000019209 bilberry extract Nutrition 0.000 claims description 13
- 229940102480 bilberry extract Drugs 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000003349 gelling agent Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 6
- 230000001112 coagulating effect Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- 239000002994 raw material Substances 0.000 abstract description 14
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract description 12
- 229960004373 acetylcholine Drugs 0.000 abstract description 12
- 230000015556 catabolic process Effects 0.000 abstract description 8
- 230000003078 antioxidant effect Effects 0.000 abstract description 7
- 210000004556 brain Anatomy 0.000 abstract description 7
- 238000006731 degradation reaction Methods 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 230000036542 oxidative stress Effects 0.000 abstract description 4
- 230000000052 comparative effect Effects 0.000 description 40
- 102000012440 Acetylcholinesterase Human genes 0.000 description 14
- 108010022752 Acetylcholinesterase Proteins 0.000 description 14
- 229940022698 acetylcholinesterase Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 230000002000 scavenging effect Effects 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 208000000044 Amnesia Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 238000003809 water extraction Methods 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 208000026139 Memory disease Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000006984 memory degeneration Effects 0.000 description 4
- 208000023060 memory loss Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002164 acetylcholinergic effect Effects 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000002481 ethanol extraction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- -1 sulfur amino acid Chemical class 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 240000007228 Mangifera indica Species 0.000 description 2
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- SMBBQHHYSLHDHF-UHFFFAOYSA-M 2-acetyloxyethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)OCC[N+](C)(C)C SMBBQHHYSLHDHF-UHFFFAOYSA-M 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 241000912433 Paulinia Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/10—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products
- A23L21/15—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products derived from fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/032—Citric acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/044—Malic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0606—Arginine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
본 발명은 다양한 천연 추출물 및 천연 원료를 포함하는 집중력 향상용 젤리형 조성물 및 그 제조 방법에 관한 것이다.The present invention relates to a jelly-type composition for improving concentration comprising various natural extracts and natural raw materials, and a method for manufacturing the same.
인간의 뇌 기능은 뇌 세포의 활성도가 높을 때 집중력 및 기억력이 높아지며, 노화가 진행될수록 또는 스트레스 등의 외적 요인에 의하여 그 기능이 감퇴된다. 그러나, 현대 사회는 경쟁 사회로써 끊임없는 학습을 요구하고 있으며, 집중력은 학습 능력에 있어서 가장 중요한 요소 중의 하나이다. 집중력은 모든 학습과 정보처리에 기초가 되는 기본적인 인지 능력으로서 이러한 능력이 부족하거나 장애를 갖게 되면 집중하는 것, 듣는 것, 그리고 기억하는 것에 어려움이 따른다. 집중력의 문제는 단순히 학업 성취의 문제만을 유발하는 것이 아니라, 주의가 산만하고 부주의하며, 충동적이고, 지나치게 활동적이며, 정서가 불안정하고, 낮은 자존감을 형성하게 되는데 이러한 문제가 심각해지면 학습하는 것, 일을 지속하는 것, 시작한 일을 끝마치는 것, 사회적 관계형성 및 대인 관계에도 영향을 미치게 된다.
이와 관련하여, 기억력 상실 및 학습능력의 상실 등의 인지기능 장애는 주로 대뇌 기저부의 아세틸콜린성 신경세포의 손상으로부터 비롯되며, 구체적으로, 뇌 세포 내에서 아세틸콜린의 공급이 저해되면 뇌의 기억 손실의 크게 영향을 미치게 되며 인지 기능이 저하된다는 연구가 보고된 바 있다 (Bulletin of Food Technology 22(1), 51-58). 그에 따라, 아세틸콜린 수용체에 대한 효능제(agonist), 아세틸콜린분해효소(AChE) 저해제 등 여러가지 작용 기전에 따라 아세틸콜린성 신경세포의 기능을 강화시켜 인지기능 향상에 도움을 줄 수 있는 약물이 개발되어 왔으며, 아세틸콜린 분해를 억제함을 통해 집중력 개선에 효과가 있는 약물들 또한 보고된 바 있다 (Current Neuropharmacology, 11(3), 315-335, 2013).Human brain function increases concentration and memory when brain cell activity is high, and its function decreases as aging progresses or external factors such as stress. However, the modern society demands continuous learning as a competitive society, and concentration is one of the most important factors in learning ability. Concentration is a basic cognitive ability that underlies all learning and information processing, and when this ability is lacking or impaired, it is difficult to concentrate, listen, and remember. Problems with concentration not only cause problems with academic achievement, but are distracted, inattentive, impulsive, overactive, emotionally unstable, and form low self-esteem. When these problems become serious, learning, work It also affects how you continue to work, finish what you start, and how you build social and interpersonal relationships.
In this regard, cognitive dysfunction, such as memory loss and loss of learning ability, mainly results from damage to acetylcholinergic neurons at the base of the brain. Studies have reported that it significantly affects the cognitive function and decreases cognitive function (Bulletin of Food Technology 22(1), 51-58). Accordingly, drugs that can help improve cognitive function by enhancing the function of acetylcholinergic neurons according to various mechanisms of action, such as agonists for acetylcholine receptors and acetylcholinesterase (AChE) inhibitors, have been developed. Drugs that are effective in improving concentration by inhibiting acetylcholine degradation have also been reported (Current Neuropharmacology, 11(3), 315-335, 2013).
한편, 겔(gel)상 제품인 젤리는 수분함량을 20% 내외로 함유한 당류 기호식품이다. 젤리는 당류와 겔화제를 혼합하여 농축 성형하여 굳힌 후 제조되며 겔화제의 종류에 따라 펙틴 젤리, 한천 젤리, 젤라틴 젤리, 전분 젤리 등으로 구분되어 다양한 조직감을 부여하므로 제조 공정에 따라서도 다양한 제품을 기대할 수 있다. 조직상으로 펙틴 젤리는 잘 끊어지고 약간의 씹힘성이 있으며, 젤라틴 젤리는 질기고 씹힘성이 뛰어나고, 전분 젤리는 다른 종류들에 비해 단단한 조직감이 특징이다 (J Korean Soc Food Sci Nutr 37(6), 792-797, 2008). 최근 소비자들은 단순한 젤리가 아닌 기능성식품 원료를 이용하여 관능 특성 및 건강 기능적 특성을 향상시킨 젤리를 선호하는 추세에 있으며, 그 제조 원료도 고급화, 다양화되고 있다.On the other hand, jelly, a gel-like product, is a sugar favorite food containing about 20% of moisture content. Jelly is manufactured after concentrating molding and hardening by mixing sugar and gelling agent. Depending on the type of gelling agent, it is divided into pectin jelly, agar jelly, gelatin jelly, starch jelly, etc. can be expected In terms of texture, pectin jellies break easily and have some chewiness, gelatin jellies are tough and chewy, and starch jellies have a firmer texture than other types (J Korean Soc Food Sci Nutr 37(6), 792). -797, 2008). Recently, consumers have a tendency to prefer jellies with improved sensory and health and functional properties using functional food raw materials rather than simple jellies, and their manufacturing raw materials are also being upgraded and diversified.
이러한 배경 하에, 본 발명자들은 테아닌 등의 천연 원료 및 과라나 추출물 등의 다양한 천연 추출물을 최적의 함량비로 혼합함으로써 우수한 항산화 활성 및 아세틸콜린 분해 억제 활성을 나타내는 것을 확인한 바, 집중력 향상을 위하여 간편하게 섭취할 수 있는 젤리 형태의 조성물을 개발하여 본 발명을 완성하였다.Under this background, the present inventors confirmed that excellent antioxidant activity and acetylcholine degradation inhibitory activity were exhibited by mixing natural raw materials such as theanine and various natural extracts such as guarana extract in an optimal content ratio, so it can be easily ingested to improve concentration. The present invention was completed by developing a composition in the form of a jelly.
본 발명의 하나의 목적은 테아닌, 과라나 추출물, 타우린, L-아르기닌, 빌베리 추출물, 및 망고 추출물을 포함하는 집중력 향상용 젤리형 조성물을 제공하는 것이다.One object of the present invention is to provide a jelly-type composition for improving concentration comprising theanine, guarana extract, taurine, L-arginine, bilberry extract, and mango extract.
본 발명의 다른 목적은 (a) 과라나, 빌베리, 및 망고를 열수 추출하는 단계; (b) 테아닌, 과라나 추출물, 타우린, L-아르기닌, 빌베리 추출물, 및 망고 추출물을 혼합하는 단계; 및 (c) 겔화제, 구연산, DL-사과산, 및 이소말토올리고당을 첨가한 후, 3-5℃에서 6 내지 24시간 동안 응고시키는 단계;를 포함하는, 집중력 향상용 젤리형 조성물의 제조 방법을 제공하는 것이다.Another object of the present invention comprises the steps of: (a) hot water extraction of guarana, bilberry, and mango; (b) mixing theanine, guarana extract, taurine, L-arginine, bilberry extract, and mango extract; and (c) adding a gelling agent, citric acid, DL-malic acid, and isomaltooligosaccharide, and then coagulating at 3-5° C. for 6 to 24 hours. will provide
이를 구체적으로 설명하면 다음과 같다. 한편, 본 발명에서 개시된 각각의 설명 및 실시형태는 각각의 다른 설명 및 실시 형태에도 적용될 수 있다. 즉, 본 발명에서 개시된 다양한 요소들의 모든 조합이 본 발명의 범주에 속한다. 또한, 하기 기술된 구체적인 서술에 의하여 본 발명의 범주가 제한된다고 볼 수 없다.This will be described in detail as follows. Meanwhile, each description and embodiment disclosed in the present invention may be applied to each other description and embodiment. That is, all combinations of the various elements disclosed herein fall within the scope of the present invention. In addition, it cannot be considered that the scope of the present invention is limited by the specific descriptions described below.
상기 목적을 달성하기 위한 본 발명의 하나의 양태는, 테아닌, 과라나 추출물, 타우린, L-아르기닌, 빌베리 추출물, 및 망고 추출물을 포함하는 집중력 향상용 젤리형 조성물을 제공한다.One aspect of the present invention for achieving the above object provides a jelly-type composition for improving concentration comprising theanine, guarana extract, taurine, L-arginine, bilberry extract, and mango extract.
본 발명의 "젤리형 조성물"은, 겔화제가 수분과 결합하여 겔(gel)을 형성할 수 있는 당류 기호식품인 젤리의 제형을 가지는 조성물을 의미한다. 본 발명의 젤리형 조성물은 본 발명의 유효성분 외에 사용 목적 등에 따라 본 발명에 따른 목적을 저해하지 않는 범위 내에서 다른 성분들이 적절히 배합될 수 있다. 구체적으로, 감미료, 항균 성분, 방부 성분, 향료, 비타민, 산화아연 등을 추가로 포함할 수 있다.The "jelly composition" of the present invention means a composition having a jelly formulation, which is a saccharide preference food in which a gelling agent can form a gel by binding with water. In the jelly-like composition of the present invention, other components may be appropriately blended within the range that does not impair the purpose of the present invention, depending on the purpose of use, etc. in addition to the active ingredient of the present invention. Specifically, it may further include a sweetener, an antibacterial component, an antiseptic component, a flavoring agent, a vitamin, zinc oxide, and the like.
본 발명의 "과라나(Paullinia cupana)"는 브라질 아마존 분지 원산의 무환자나무과 폴리니아속의 덩굴 식물이다. 과라나에는 헤오브로민(heobromine), 테오필린(theophylline), 카페인(caffeine), 아데닌(adenine) 및 잔틴(xanthine) 등의 성분이 함유되어 있으며, 그 성분 중 카페인은 커피 또는 녹차에 함유된 카페인과 달리 신경을 자극하지 않는 것으로 알려져 있다. 미국 식품의약국(FDA)은 과라나를 일반적으로 안정하다고 인정되는 물질(GRAS)로 지정하여 분류하고 있으며, 생리활성과 관련하여 변비, 설사, 소화불량, 신경통 등의 치료 효능, 항균 활성, 항노화 활성 등이 보고되었다. 과라나 추출물은 에너지 음료에 포함되어 제품화된 바 있으나, 과라나 추출물이 젤리의 제조에 이용되어 그 집중력 향상 용도에 대해서는 연구된 바 없다. "Guarana ( Paullinia cupana )" of the present invention is a vine of the genus Paulinia, native to the Amazon Basin of Brazil. Guarana contains components such as heobromine, theophylline, caffeine, adenine, and xanthine. It is otherwise known to not stimulate nerves. The U.S. Food and Drug Administration (FDA) has designated and classified guarana as a substance that is generally recognized as stable (GRAS). activity has been reported. Guarana extract has been included in energy drinks and has been commercialized, but the use of guarana extract for manufacturing jelly has not been studied for its concentration-improving use.
본 발명에서 과라나 추출물은 카페인(caffein) 함량이 10 내지 30%일 수 있으며, 원료에 따라서 함량 차이가 있을 수 있으므로 적용 가능한 카페인 함량은 20 내지 25% 범위인 것이 바람직하다.In the present invention, the guarana extract may have a caffeine content of 10 to 30%, and since there may be a content difference depending on the raw material, the applicable caffeine content is preferably in the range of 20 to 25%.
본 발명에서 과라나 추출물은 10 내지 30 중량부 포함되는 것이 바람직하며, 그 함량이 10 중량부 미만인 경우에는 원하는 효능을 얻을 수 없고, 30 중량부 이하에서 최적의 효과를 얻을 수 있다. 본 발명의 구체적인 일 구현예에서는 과라나 추출물이 소량(5 중량부) 포함된 비교예 1 및 과라나 추출물이 과량(35 중량부) 포함된 비교예 2 조성물의 DPPH 소거능 및 AChE 저해능이 20 중량부 포함된 실시예 조성물에 비해 낮은 바, 과라나 추출물이 적절한 비율로 혼합되었을 때 더 뛰어난 효과를 나타냄을 알 수 있었다. In the present invention, the guarana extract is preferably included in 10 to 30 parts by weight, and when the content is less than 10 parts by weight, the desired effect cannot be obtained, and the optimal effect can be obtained in 30 parts by weight or less. In a specific embodiment of the present invention, the DPPH scavenging ability and AChE inhibitory ability of the composition of Comparative Example 1 containing a small amount (5 parts by weight) of the guarana extract and the composition of Comparative Example 2 containing an excessive amount (35 parts by weight) of the guarana extract was 20 parts by weight. It was found that when the lower bar compared to the composition of the example, the guarana extract was mixed in an appropriate ratio, a more excellent effect was exhibited.
본 발명의 "빌베리(Vaccinium myrtillus, bilberry)"는 유럽블루베리로도 불리는 파란 빛깔의 식용 과일로써, 북유럽에서는 일반적으로 자연에서 직접 채취하여 잼이나 소스를 제조한다. 빌베리는 안토시아닌(anthocyanin) 색소를 다량 함유하고 있어 일반적으로 눈에 좋다고 알려져 있다 (Nutrition, Metabolism and Cardiovascular Diseases, 22(1), 72-80, 2012). 최근에는 유럽뿐만 아니라 일본과 미국에서도 건강식품이나 식품소재로써 널리 이용되고 있으며, 항산화 작용 및 혈관개선 작용 등에 대하여 보고되었다. 다만, 빌베리 추출물이 젤리의 제조에 이용되어 그 집중력 향상 용도에 대해서는 연구된 바 없다."Bilberry ( Vaccinium myrtillus , bilberry)" of the present invention is a blue-colored edible fruit also called European blueberry, and in Northern Europe, it is generally collected directly from nature to produce jam or sauce. Bilberry contains a large amount of anthocyanin pigment and is generally known to be good for the eyes (Nutrition, Metabolism and Cardiovascular Diseases, 22(1), 72-80, 2012). Recently, it has been widely used as a health food or food material not only in Europe but also in Japan and the United States, and has been reported for its antioxidant action and blood vessel improvement action. However, the use of bilberry extract for the manufacture of jelly has not been studied for its concentration improvement use.
본 발명의 "망고(Mangifera indica)"는 옻나무과(Anacardiaceae) 망고속(Mangifera)에 속하는 다년생의 열대과일이다. 완숙 망고에는 페놀 화합물, 베타카로틴, 비타민 C 및 미네랄과 같은 다양한 생리활성 화합물이 함유되어 있으며, 그 중 주된 성분인 mangiferin은 항염증, 항당뇨병, 면역 조절, 항종양과 같은 다양한 생리활성을 갖는 것으로 밝혀져 있다. 열대·아열대 과일은 이국적인 향미와 관능적 특성을 가지고 있을 뿐만 아니라 영양적 가치가 우수하며 생리활성물질이 다양하게 함유되어 있는 것으로 밝혀져 많은 연구들이 이루어지고 있으나, 망고 추출물이 젤리의 제조에 이용되어 그 집중력 향상 용도에 대해서는 연구된 바 없다."Mango ( Mangifera indica )" of the present invention is a perennial tropical fruit belonging to the genus Mangifera of the family Anacardiaceae. Ripe mango contains various physiologically active compounds such as phenolic compounds, beta-carotene, vitamin C and minerals. has been revealed Tropical and subtropical fruits not only have exotic flavor and sensual characteristics, but also have excellent nutritional value and contain various physiologically active substances. The use of enhancement has not been studied.
본 발명에서 용어 "추출물"은 용매와 추출 원료를 특정 조건 하에서 접촉시킴으로써 추출 원료에 함유된 유효성분으로 원료에 함유된 성분을 분리해 낼 수 있다면, 추출 방법이나 유효성분의 종류에 무관하게 모두 포함될 수 있다. 예컨대, 물이나 유기용매를 이용하여 원료로부터 용매에 용해되는 성분을 추출한 것, 원료의 특정 성분, 예컨대 오일과 같은 특정 성분만을 추출하여 얻어진 것 등을 모두 포함할 수 있다. 상기 추출물은 건조 후 분말화하거나, 열수 추출법, 에탄올 추출법 등 종래 알려진 다양한 추출법에 의해 수득할 수 있다. 상기 추출물은 물, 탄소수 1 내지 4개의 무수 또는 함수 저급 알코올, 아세톤, 석유에테르, 에틸아세테이트, 부틸아세테이트, 트리클로로메탄, 디클로로메탄, 클로로포름, 헥산 및 1,3-부틸렌글리콜로 이루어진 군으로부터 선택되는 하나 이상의 용매로 추출될 수 있다. 본 발명에서는 구체적으로, 90 내지 100℃의 열수로 5시간 동안 추출한 것일 수 있으나 이에 제한되지 않는다.In the present invention, the term "extract" is an active ingredient contained in the extraction raw material by contacting the solvent and the extraction raw material under specific conditions, so long as it is possible to separate the ingredients contained in the raw material, regardless of the extraction method or the type of the active ingredient can For example, extracts of components soluble in solvents from raw materials using water or organic solvents, and extracts obtained by extracting only specific components such as specific components of raw materials, such as oil, may be included. The extract may be powdered after drying, or may be obtained by various conventionally known extraction methods such as hot water extraction and ethanol extraction. The extract is selected from the group consisting of water, anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms, acetone, petroleum ether, ethyl acetate, butyl acetate, trichloromethane, dichloromethane, chloroform, hexane and 1,3-butylene glycol It can be extracted with one or more solvents. Specifically, in the present invention, it may be extracted for 5 hours with hot water of 90 to 100 ℃, but is not limited thereto.
본 발명의 구체적인 일 구현예에서는, 과라나, 빌베리, 및 망고를 열수 추출한 추출물을 포함하는 조성물과, 100% 에탄올 추출한 추출물을 포함하는 조성물의 생리활성을 비교한 결과, 열수 추출물을 포함하는 실시예 1 조성물이 에탄올 추출물을 포함하는 비교예 5 조성물에 비하여 DPPH 소거능 및 acetylcholinesterase(AChE) 저해 활성이 높은 것을 확인하였다 (실험예 1 및 2). 즉, 추출 용매에 따라 본 발명 조성물의 효과에 영양을 미치며, 열수 추출물을 포함하는 경우 에탄올 추출물에 비하여 집중력 향상 효과가 더 높을 것임을 유추할 수 있다.In a specific embodiment of the present invention, as a result of comparing the physiological activity of a composition comprising an extract obtained by hot water extraction of guarana, bilberry, and mango with a composition comprising an extract extracted with 100% ethanol, Example 1 comprising a hot water extract It was confirmed that the composition had higher DPPH scavenging ability and acetylcholinesterase (AChE) inhibitory activity than the composition of Comparative Example 5 including the ethanol extract (Experimental Examples 1 and 2). That is, it can be inferred that the effect of the composition of the present invention is affected depending on the extraction solvent, and the concentration improvement effect will be higher when the hot water extract is included as compared to the ethanol extract.
본 발명의 과라나, 빌베리, 및 망고는 직접 채취하거나, 시중에 유통되는 상품을 구입하여 사용하는 등 그 입수 방법은 제한되지 않는다. 상기 과라나, 빌베리, 및 망고는 원물을 이용하거나, 건조물 또는 분말을 이용하는 등 유효성분을 추출할 수 있다면 그 형태는 제한되지 않는다.Guarana, bilberry, and mango of the present invention are directly collected, or a commercially available product is purchased and used, and the acquisition method thereof is not limited. The form of the guarana, bilberry, and mango is not limited as long as the active ingredient can be extracted by using the raw material, or using a dried product or powder.
본 발명의 "테아닌(theanine)"은 분자식 C7H14N2O3, Cas number 3081-61-6의 화합물로써, 그 분자 구조는 다음과 같다."Theanine" of the present invention is a compound of the molecular formula C 7 H 14 N 2 O 3 , Cas number 3081-61-6, and its molecular structure is as follows.
상기 테아닌은 녹차에 풍부하게 함유되어 있는 아미노산으로, 뇌 신경세포에서 GABA의 수치를 올리고, 알코올성 간 손상을 완화할 수 있음이 보고되었다. 또한, 테아닌은 스트레스로 인한 긴장감 완화에 도움을 준다고 알려져 있으나, 테아닌이 젤리 조성물의 유효성분으로 포함되어 그 집중력 향상 용도에 대해서는 연구된 바 없다. 본 발명의 테아닌은 화학적 또는 미생물학적 방법으로 직접 합성하거나, 시중에 유통되는 상품을 구입하여 사용하는 등 그 입수 방법은 제한되지 않는다.The theanine is an amino acid abundantly contained in green tea, and it has been reported that it can increase the level of GABA in brain neurons and alleviate alcoholic liver damage. In addition, theanine is known to help relieve tension due to stress, but theanine is included as an active ingredient in the jelly composition, so the use of concentration improvement has not been studied. The theanine of the present invention may be directly synthesized by chemical or microbiological methods, or a commercially available product may be purchased and used, and the method of obtaining the theanine is not limited.
본 발명의 "타우린(taurine, 2-aminoethanesulfonic acid)"은 분자식 C2H7NO3S, Cas number 107-35-7의 화합물로써, 그 분자 구조는 다음과 같다."Taurine (2-aminoethanesulfonic acid)" of the present invention is a compound of the molecular formula C 2 H 7 NO 3 S, Cas number 107-35-7, and the molecular structure is as follows.
상기 타우린은 설폰기를 산기로 하는 황아미노산의 일종으로, 인체에 널리 분포되어 있으며, 특히 골격근, 심장근, 뇌하수체, 혈소판, 림프아세포, 신장 및 망막에 고농도로 분포되어 있다. 타우린은 삼투압 조절, 세포 증식, 칼슘의 유입과 유출, 당대사 촉진, 신경 흥분 조절, 해독 작용, 세포막 안정성과 망막색소, 상피세포 증식 촉진 등을 포함한 광범위한 기능을 가지고 있음이 알려져 있다. 다만, 타우린이 젤리 조성물의 유효성분으로 포함되어 그 집중력 향상 용도에 대해서는 연구된 바 없다.The taurine is a kind of sulfur amino acid having a sulfonic acid group, and is widely distributed in the human body, and is particularly distributed in high concentrations in skeletal muscle, cardiac muscle, pituitary gland, platelets, lymphoblasts, kidneys and retina. Taurine is known to have a wide range of functions, including osmotic pressure regulation, cell proliferation, calcium inflow and outflow, glucose metabolism promotion, nerve excitability regulation, detoxification, cell membrane stability, retinal pigment, and epithelial cell proliferation promotion. However, since taurine is included as an active ingredient in the jelly composition, there has been no research on its use to improve concentration.
본 발명의 "L-아르기닌(L-arginine)"은 분자식 C6H14N4O2, Cas number 7200-25-1의 화합물로써, 그 분자 구조는 다음과 같다."L-arginine (L-arginine)" of the present invention is a compound of the molecular formula C 6 H 14 N 4 O 2 , Cas number 7200-25-1, and its molecular structure is as follows.
상기 L-아르기닌은 모든 생물체에 존재하는 조건부 필수 아미노산으로, 항동맥경화성 작용, 항산화 작용, 면역조절 기능, 상처치유, 신장질환 예방 및 방광염 치료 효과, 발기부전 치료, 성장호르몬 방출 촉진 작용과 근육 보존, 체지방 감소작용 등 다양한 효능이 보고되었다. 다만, L-아르기닌이 젤리 조성물의 유효성분으로 포함되어 그 집중력 향상 용도에 대해서는 연구된 바 없다.The L-arginine is a conditionally essential amino acid present in all living organisms, and has anti-arteriosclerotic action, antioxidant action, immunomodulatory function, wound healing, kidney disease prevention and cystitis treatment effect, erectile dysfunction treatment, growth hormone release promoting action and muscle preservation. , various effects such as reducing body fat have been reported. However, since L-arginine is included as an active ingredient in the jelly composition, there has been no research on its use to improve concentration.
본 발명의 조성물은 테아닌 10 중량부, 과라나 추출물 20 중량부, 타우린 50 중량부, L-아르기닌 70 중량부, 빌베리 추출물 5 중량부, 및 망고 추출물 40 중량부를 포함한다. 본 발명에서는 상기 테아닌, 과라나 추출물, 타우린, L-아르기닌, 빌베리 추출물, 및 망고 추출물의 혼합비에 따라 젤리형 조성물의 생리활성 및 젤리의 기호성에 미치는 영향에 대하여 평가하였다. 본 발명의 구체적인 일 구현예에서는, 테아닌 10 중량부, 과라나 추출물 20 중량부, 타우린 50 중량부, L-아르기닌 70 중량부, 빌베리 추출물 5 중량부, 및 망고 추출물 40 중량부를 포함하는 실시예 1의 조성물이 각 추출물을 상이한 중량비로 포함하는 비교예 3 조성물에 비하여 아세틸콜린 분해 억제능이 높았으며 (실험예 2), 각 추출물을 상이한 중량비로 포함하는 비교예 4 조성물에 비하여 맛에 대한 선호도가 높은 것을 확인하였다 (실험예 3). 즉, 본 발명은 집중력 향상용 젤리 형태의 조성물에 있어서, 그 영양성 및 기호성을 가장 높일 수 있는 최적화된 각 유효성분의 혼합비를 규명한 것에 그 특징이 있다.The composition of the present invention includes 10 parts by weight of theanine, 20 parts by weight of guarana extract, 50 parts by weight of taurine, 70 parts by weight of L-arginine, 5 parts by weight of bilberry extract, and 40 parts by weight of mango extract. In the present invention, the effect of the theanine, guarana extract, taurine, L-arginine, bilberry extract, and mango extract on the physiological activity of the jelly-type composition and the palatability of the jelly was evaluated according to the mixing ratio. In a specific embodiment of the present invention, in Example 1 comprising 10 parts by weight of theanine, 20 parts by weight of guarana extract, 50 parts by weight of taurine, 70 parts by weight of L-arginine, 5 parts by weight of bilberry extract, and 40 parts by weight of mango extract The composition had a high acetylcholine degradation inhibitory ability compared to the composition of Comparative Example 3 containing each extract in a different weight ratio (Experimental Example 2), and the preference for taste was high compared to the composition of Comparative Example 4 containing each extract in a different weight ratio. It was confirmed (Experimental Example 3). That is, the present invention is characterized in that in the composition in the form of a jelly for improving concentration, the mixing ratio of each active ingredient that is optimized that can maximize the nutritional and palatability of the composition has been identified.
본 발명의 조성물은 집중력뿐만 아니라 기억력을 증진시키는 것을 특징으로 한다. 기억력 상실 및 학습력 저하 등의 각종 인지장애는 주로 대뇌기저부의 아세틸콜린성 신경세포의 손상으로부터 기인된다. 구체적으로, 아세틸콜린 분해효소(acetylcholinesterase, AChE)는 acetylcholine을 분해하는 효소로써 이 효소로 인한 acetylcholine 부족 시 기억력 감퇴와 인지능력 부족 등 뇌기능 문제를 일으킨다. 이에, 본 발명에서는 조성물이 아세틸콜린 분해효소의 작용을 억제하여 아세틸콜린 분해를 억제함으로써 기억력 향상에 도움을 줄 수 있음을 확인하였다 (실험예 2). The composition of the present invention is characterized by enhancing concentration as well as memory. Various cognitive disorders such as memory loss and learning ability are mainly caused by damage to acetylcholinergic neurons at the base of the brain. Specifically, acetylcholinesterase (AChE) is an enzyme that decomposes acetylcholine, and when acetylcholine is insufficient due to this enzyme, it causes brain function problems such as memory loss and cognitive deficit. Therefore, in the present invention, it was confirmed that the composition can help improve memory by inhibiting the action of acetylcholine degrading enzyme to inhibit acetylcholine degradation (Experimental Example 2).
본 발명의 다른 하나의 양태는 (a) 과라나, 빌베리, 및 망고를 열수 추출하는 단계; (b) 테아닌, 과라나 추출물, 타우린, L-아르기닌, 빌베리 추출물, 및 망고 추출물을 혼합하는 단계; 및 (c) 겔화제, 구연산, DL-사과산, 및 이소말토올리고당을 첨가한 후, 3-5 ℃에서 6 내지 24시간 동안 응고시키는 단계;를 포함하는, 집중력 향상용 젤리형 조성물의 제조 방법을 제공한다.Another aspect of the present invention comprises the steps of: (a) hot water extraction of guarana, bilberry, and mango; (b) mixing theanine, guarana extract, taurine, L-arginine, bilberry extract, and mango extract; and (c) adding a gelling agent, citric acid, DL-malic acid, and isomaltooligosaccharide, and then coagulating at 3-5 ° C. for 6 to 24 hours. to provide.
상기 용어 "과라나", "빌베리", "망고", "테아닌", "타우린", "L-아르기닌", "추출물", 및 "젤리형 조성물"에 대한 설명은 전술한 바와 같다.The terms “guarana”, “bilberry”, “mango”, “theanine”, “taurine”, “L-arginine”, “extract”, and “jelly composition” are the same as described above.
본 발명의 겔화제는 물에 분산된 후 응고되어 겔 형태를 나타낼 수 있도록 하는 물질로써, 펙틴, 젤라틴, 한천, 알긴산, 곤약 분말, 및 카라기난 등을 사용할 수 있다. 본 발명에서는 젤라틴을 사용하였으나, 이에 제한되지 않는다.The gelling agent of the present invention is a material that solidifies after being dispersed in water to exhibit a gel form, and may include pectin, gelatin, agar, alginic acid, konjac powder, carrageenan, and the like. In the present invention, gelatin was used, but the present invention is not limited thereto.
본 발명의 구연산, DL-사과산, 및 이소말토올리고당(IMO)은 감미료로써 포함될 수 있다. Citric acid, DL-malic acid, and isomaltooligosaccharide (IMO) of the present invention may be included as a sweetener.
본 발명의 젤리형 조성물은 구체적으로, 정제수 200 중량부에 겔화제 10 중량부를 넣어 녹인 후, 구연산 20 중량부, DL-사과산 7 중량부, 이소말토올리고당 25 중량부를 혼합 후 가열하고, 테아닌, 과라나 추출물, 타우린, L-아르기닌, 빌베리 추출물, 및 망고 추출물이 혼합된 혼합물 80 중량부를 첨가한 후, 4℃에서 12시간 응고하여 제조될 수 있다.Specifically, the jelly-like composition of the present invention is dissolved by putting 10 parts by weight of a gelling agent in 200 parts by weight of purified water, then mixing 20 parts by weight of citric acid, 7 parts by weight of DL-malic acid, and 25 parts by weight of isomaltooligosaccharide, followed by heating, theanine, guarana After adding 80 parts by weight of a mixture of the extract, taurine, L-arginine, bilberry extract, and mango extract, it may be prepared by coagulation at 4° C. for 12 hours.
본 발명의 조성물은 산화적 스트레스로부터 뇌를 보호하는 항산화 효능 및 아세틸콜린 분해 억제 활성이 우수하여 집중력 및 기억력 향상에 도움을 줄 수 있으며, 젤리 형태로써 맛과 식감이 뛰어나고 섭취가 간편하다.The composition of the present invention has excellent antioxidant efficacy and acetylcholine degradation inhibitory activity to protect the brain from oxidative stress, and thus can help improve concentration and memory.
이하 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 국한되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.
제조예 1. 집중력 향상용 조성물의 제조Preparation Example 1. Preparation of a composition for improving concentration
본 발명의 테아닌, 과라나 추출물, 타우린, L-아르기닌, 빌베리 추출물, 및 망고 추출물을 포함하는 집중력 향상용 조성물은 다음 표 1의 중량비로 혼합하여 제조되었다. The composition for improving concentration, including the theanine, guarana extract, taurine, L-arginine, bilberry extract, and mango extract of the present invention, was prepared by mixing in the weight ratio shown in Table 1 below.
구체적으로, 과라나(Paullinia cupana), 빌베리(Vaccinium myrtillus), 및 망고(Mangifera indica) 원물을 준비하고, 각 원물 중량의 10배수의 증류수를 첨가하고, 5시간 동안 95℃의 온도에서 열수 추출을 진행하여 추출물을 제조하였다. 비교예 5 조성물의 경우, 열수 대신 100% 에탄올을 이용하여 추출된 추출물을 이용하여 제조하였다.Specifically, guarana ( Paullinia cupana ), bilberry ( Vaccinium myrtillus ), and mango ( Mangifera indica ) Prepare a raw material, add distilled water 10 times the weight of each raw material, and proceed with hot water extraction at a temperature of 95 ° C. for 5 hours to prepare an extract. In the case of the composition of Comparative Example 5, an extract extracted using 100% ethanol instead of hot water was prepared.
실험예 1. DPPH 소거 활성 평가Experimental Example 1. Evaluation of DPPH scavenging activity
산화적 스트레스에 의한 뇌 세포의 괴사는 단기적으로는 집중력 및 기억력의 저하 뿐만 아니라 장기적으로 뇌 기능의 저하를 일으킬 수 있다. DPPH(2,2-Diphenyl-1-picrylhydrazyl)는 과다하게 산화되면 산화 작용을 일으켜 염증 반응을 나타내는 물질이므로, 이들이 시험물질과 반응하여 활성화가 감소되면, 뇌에서도 그 활성이 감소되는 것으로 예측할 수 있다. 이에, 본 발명의 조성물이 항산화 효과를 갖는지를 확인하기 위하여 in vitro DPPH 자유라디칼 제거능을 평가하였다. Necrosis of brain cells due to oxidative stress can cause a decrease in concentration and memory in the short term as well as a decrease in brain function in the long term. DPPH (2,2-Diphenyl-1-picrylhydrazyl) is a substance that causes an oxidative reaction when it is oxidized excessively and shows an inflammatory reaction. . Accordingly, in vitro DPPH free radical removal ability was evaluated to confirm whether the composition of the present invention has an antioxidant effect.
구체적으로, 각 조성물 100μl에 100μm DPPH를 함유한 메탄올 용액 2ml를 가해 진탕하여 실온에서 10분간 방치한 후 분광광도계를 이용하여 517nm에서 흡광도를 측정하였다. Specifically, to 100 μl of each composition, 2 ml of a methanol solution containing 100 μm DPPH was added, shaken, and left at room temperature for 10 minutes, and then absorbance was measured at 517 nm using a spectrophotometer.
그 결과 상기 표 2에 나타난 바와 같이, 실시예 1 조성물을 처리하자 DPPH 소거 활성이 가장 현저히 증가한 것을 확인하였다. 그에 반해, 각 추출물을 에탄올 추출한 비교예 5 조성물의 자유라디칼 소거능은 다소 떨어지는 바, 빌베리 등의 천연물을 열수로 추출한 경우에 항산화 효능을 나타내는 유효성분들이 더 많이 추출되는 것임을 알 수 있었다. As a result, as shown in Table 2, it was confirmed that the DPPH scavenging activity was most significantly increased when the composition of Example 1 was treated. In contrast, the free radical scavenging ability of the composition of Comparative Example 5 obtained by ethanol extraction of each extract was somewhat lower, and it was found that more active ingredients exhibiting antioxidant efficacy were extracted when natural products such as bilberry were extracted with hot water.
또한, 과라나 추출물이 소량 포함된 비교예 1 조성물의 경우 DPPH 소거 활성이 가장 낮은 바, 본 발명의 과라나 추출물은 테아닌 등의 유효성분 및 다른 천연 추출물과 함께 젤리형 조성물에 포함되어 뇌의 산화적 스트레스 감소에 효과를 줄 수 있음을 알 수 있다.In addition, in the case of the composition of Comparative Example 1 containing a small amount of guarana extract, the DPPH scavenging activity is the lowest, and the guarana extract of the present invention is included in a jelly-like composition together with active ingredients such as theanine and other natural extracts to induce oxidative stress in the brain. It can be seen that it can have an effect on the reduction.
실험예 2. Acetylcholinesterase(AChE) 저해 활성 평가Experimental Example 2. Acetylcholinesterase (AChE) inhibitory activity evaluation
알츠하이머성 치매로부터 유발되는 기억력 상실 및 학습력 저하 등 각종 인지장애는 주로 대뇌기저부의 acetylcholine성 신경세포의 손상으로부터 기인된다는 가설을 바탕으로, 본 발명의 조성물이 아세틸콜린 분해를 억제함으로써 기억력과 인식력을 향상시킬 수 있는지를 평가하였다. Based on the hypothesis that various cognitive disorders, such as memory loss and learning loss caused by Alzheimer's dementia, are mainly caused by damage to acetylcholine neurons at the base of the brain, the composition of the present invention improves memory and cognition by inhibiting the breakdown of acetylcholine It was evaluated whether it could be done.
구체적으로, AChE 저해활성 측정은 acetylcholine iodide를 기질로 사용하여 측정하였으며, 효소는 PC12 세포배양액을 2,000 rpm에서 6분간 원심분리 하여 상등액을 제거하고, 균질화를 위한 buffer(1M NaCl, 1% Triton X-100 혼합액에 10 mM Tris-HCl로 pH 7.2로 조정) 2mL를 첨가하여 Glass-Col homogenizer로 균질화한 후 균질화된 세포배양액을 12,000rpm에서 30분 동안 원심분리 하였으며, 그 상등액을 효소실험을 위하여 사용하였다. 모든 추출공정은 4℃에서 수행하였으며, 추출한 효소액의 단백질 함량을 측정하기 위하여 Quant-iTTM Protein Assay kit를 이용하여 측정하였다. 효소 10μL에 조성물 10μL를 넣어 37℃에서 15분간 pre-incubation 시킨 후, 반응 혼합물에 50 mM sodium phosphate buffer(pH 8.0)에 용해시킨 Ellman's reaction mixture 70μL를 첨가한 후 405nm에서 10분 동안 2분 간격으로 흡광도를 측정하였다.Specifically, AChE inhibitory activity was measured using acetylcholine iodide as a substrate, and the enzyme was centrifuged at 2,000 rpm for 6 minutes to remove the supernatant, and buffer (1M NaCl, 1% Triton X-) for homogenization. 100 mixture was added with 10 mM Tris-HCl to adjust pH to 7.2), 2 mL was added and homogenized with a Glass-Col homogenizer, and the homogenized cell culture solution was centrifuged at 12,000 rpm for 30 minutes, and the supernatant was used for enzyme experiments . All extraction processes were performed at 4° C., and the Quant-iTTM Protein Assay kit was used to measure the protein content of the extracted enzyme solution. Add 10 μL of composition to 10 μL of enzyme and pre-incubate at 37° C. for 15 minutes. Then, 70 μL of Ellman's reaction mixture dissolved in 50 mM sodium phosphate buffer (pH 8.0) was added to the reaction mixture, followed by 2 minutes at 405 nm for 10 minutes. Absorbance was measured.
그 결과 상기 표 3에 나타난 바와 같이, 실시예 1 조성물은 AChE 저해 활성이 약 70.3%로 비교예 1 내지 5 조성물에 비하여 아세틸콜린 분해 억제 효능이 우수한 것을 알 수 있었다. 과라나 추출물이 소량(5 중량부) 포함된 비교예 1 및 과라나 추출물이 과량(35 중량부) 포함된 비교예 2 조성물은 AChE 저해능이 실시예 조성물에 비해 낮은 바, 과라나 추출물이 적절한 비율로 혼합되었을 때 더 뛰어난 효과를 나타냄을 알 수 있었다. As a result, as shown in Table 3, the composition of Example 1 had an AChE inhibitory activity of about 70.3%, and it was found that the acetylcholine degradation inhibitory effect was excellent compared to the compositions of Comparative Examples 1 to 5. Comparative Example 1 containing a small amount (5 parts by weight) of the guarana extract and the composition of Comparative Example 2 containing an excess (35 parts by weight) of the guarana extract had lower AChE inhibitory ability compared to the composition of the example, so the guarana extract was mixed in an appropriate ratio. It was found that a better effect was exhibited when
또한, 빌베리 등의 천연물을 에탄올 추출한 비교예 5 조성물 역시 AChE 저해능이 실시예 조성물에 비해 낮았는데, 이를 통해 각 천연물을 열수로 추출한 경우, 각 천연물에 함유된 아세틸콜린 분해 억제 효능과 관련된 유효성분들이 100% 에탄올로 추출한 경우에 비하여 더 많은 함량으로 추출된 것으로 유추할 수 있다.In addition, the composition of Comparative Example 5 obtained by ethanol extraction of natural products such as bilberry also had lower AChE inhibitory ability than the composition of Example. It can be inferred that it is extracted with a higher content than when extracted with 100% ethanol.
제조예 2. 집중력 향상용 젤리의 제조Preparation Example 2. Preparation of jelly for improving concentration
200g의 물을 중탕하면서 겔화제로써 10g의 카라기난(carrageenan)을 넣어 녹인 후, 구연산 20g, DL-사과산 7g, 및 이소말토올리고당(IMO) 25g을 넣어 80℃까지 가열하였다. 이어서, 각 실시예 및 비교예 조성물을 80g 첨가한 다음, 균일하게 혼합하고 이것을 밀폐용기에 넣어 상온에서 30분간 식힌 다음 4℃ 냉장고에서 12시간 성형하여 실시예 및 비교예 젤리를 제조하였다.After dissolving 10 g of carrageenan as a gelling agent while boiling 200 g of water, 20 g of citric acid, 7 g of DL-malic acid, and 25 g of isomaltooligosaccharide (IMO) were added and heated to 80°C. Then, 80 g of each Example and Comparative Example composition was added, mixed uniformly, put in an airtight container, cooled at room temperature for 30 minutes, and molded in a refrigerator at 4° C. for 12 hours to prepare Example and Comparative Example jelly.
실험예 3. 관능 평가Experimental Example 3. Sensory evaluation
본 발명의 방법으로 제조된 젤리의 주관적인 기호도를 평가하기 위하여 실시예 및 비교예의 젤리를 대상으로 비교 관능평가를 실시하였다. 구체적으로, 성인남녀 20명을 대상으로 본 발명의 실시예 1 및 비교예 1 내지 5의 젤리를 섭취하도록 한 후, 30분 간 평가를 진행하였다. 주관적 효과 평가는 측정자가 느끼는 섭취 전후의 인지적 변화의 질문을 통하여 10점 척도로 평가하였으며, 변화 없음을 0점으로 하고, 확실한 기능성을 인지하였을 때 또는 선호도가 높을 때 10점을 체크하도록 하였다. 젤리의 맛, 집중력 향상 정도, 스트레스 해소, 및 전체적인 기호도 4가지 항목에 대하여 질문하였다. In order to evaluate the subjective preference of the jelly prepared by the method of the present invention, comparative sensory evaluation was performed on the jelly of Examples and Comparative Examples. Specifically, 20 adult men and women were allowed to ingest the jelly of Example 1 and Comparative Examples 1 to 5 of the present invention, and then the evaluation was performed for 30 minutes. Subjective effect evaluation was evaluated on a 10-point scale through the question of cognitive changes before and after intake felt by the measurer. The taste of jelly, the degree of concentration improvement, stress relief, and overall preference were also asked about 4 items.
그 결과 상기 표 4에 나타난 바와 같이, 실시예 1의 젤리가 전체적으로 높은 평가를 받았으며, 특히, 그 맛과 주관적인 집중력 향상에 대한 평가가 우수한 것을 알 수 있었다. 비교예 4 젤리의 경우, 맛과 주관적인 스트레스 해소 정도에 대한 평가가 낮았는데, 이는 망고 추출물이 상대적으로 소량 포함되어 관능적 평가에서 약간의 거부감이 나타나는 것으로 판단되었다. As a result, as shown in Table 4, the jelly of Example 1 received a high overall evaluation, and in particular, it was found that the taste and the evaluation of the subjective improvement of concentration were excellent. Comparative Example 4 In the case of jelly, the taste and subjective stress relieving degree were low, which was judged to be slightly repulsive in sensory evaluation because a relatively small amount of mango extract was included.
또한, 과라나 추출물이 소량 포함된 비교예 1 젤리 및 과라나 추출물이 과량 포함된 비교예 2 젤리는 집중력 향상 및 스트레스 해소 정도에 대한 평가가 낮은 바, 주관적 평가에 있어서도 과라나 추출물의 바람직한 혼합비가 중요한 것을 알 수 있었다.In addition, Comparative Example 1 jelly containing a small amount of guarana extract and Comparative Example 2 jelly containing an excessive amount of guarana extract had low evaluations of concentration improvement and stress relief. could
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art to which the present invention pertains will understand that the present invention may be embodied in other specific forms without changing the technical spirit or essential characteristics thereof. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention, rather than the above detailed description, all changes or modifications derived from the meaning and scope of the claims described below and their equivalents.
Claims (4)
상기 각 추출물은 90 내지 100℃의 열수로 5시간 동안 추출된 것인, 집중력 향상용 젤리형 조성물.
10 parts by weight of theanine, 20 parts by weight of guarana extract, 50 parts by weight of taurine, 70 parts by weight of L-arginine, 5 parts by weight of bilberry extract, and 40 parts by weight of mango extract as a jelly-type composition for improving concentration, comprising:
Each of the extracts is extracted for 5 hours with hot water of 90 to 100 ℃, a jelly-type composition for improving concentration.
(b) 테아닌, 과라나 추출물, 타우린, L-아르기닌, 빌베리 추출물, 및 망고 추출물을 혼합하는 단계; 및
(c) 겔화제, 구연산, DL-사과산, 및 이소말토올리고당을 첨가한 후, 3-5℃에서 6 내지 24시간 동안 응고시키는 단계;를 포함하는, 제1항 집중력 향상용 젤리형 조성물의 제조 방법.
(a) hydrothermal extraction of guarana, bilberry, and mango;
(b) mixing theanine, guarana extract, taurine, L-arginine, bilberry extract, and mango extract; and
(c) adding a gelling agent, citric acid, DL-malic acid, and isomaltooligosaccharide, and then coagulating at 3-5°C for 6 to 24 hours; Way.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210086590A KR102328028B1 (en) | 2021-07-01 | 2021-07-01 | Jelly type composition for enhancing concentration |
| KR1020210155587A KR102649086B1 (en) | 2021-07-01 | 2021-11-12 | Manufacturing method of jelly comprising natural ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210086590A KR102328028B1 (en) | 2021-07-01 | 2021-07-01 | Jelly type composition for enhancing concentration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210155587A Division KR102649086B1 (en) | 2021-07-01 | 2021-11-12 | Manufacturing method of jelly comprising natural ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102328028B1 true KR102328028B1 (en) | 2021-11-17 |
Family
ID=78702674
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210086590A KR102328028B1 (en) | 2021-07-01 | 2021-07-01 | Jelly type composition for enhancing concentration |
| KR1020210155587A KR102649086B1 (en) | 2021-07-01 | 2021-11-12 | Manufacturing method of jelly comprising natural ingredient |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210155587A KR102649086B1 (en) | 2021-07-01 | 2021-11-12 | Manufacturing method of jelly comprising natural ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (2) | KR102328028B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002322063A (en) * | 2001-04-25 | 2002-11-08 | Ito En Ltd | Composition for relieving mental fatigue, composition for maintaining and enhancing concentration power, and composition for maintaining and enhancing mental vitality |
| KR20130000664A (en) * | 2011-06-23 | 2013-01-03 | 농업회사법인 맑은내일 주식회사 | Composition with stimulating effect, comprising the extract of medicinal plants |
| KR102070701B1 (en) * | 2019-05-02 | 2020-01-29 | (주)오르나 | Composition for antioxidant comprising bilberry juice, sea buckthorn juice, lingonberry juice |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10537604B2 (en) * | 2016-07-19 | 2020-01-21 | Nektium Pharma, S.L. | Compositions for enhancing brain activity |
-
2021
- 2021-07-01 KR KR1020210086590A patent/KR102328028B1/en active IP Right Grant
- 2021-11-12 KR KR1020210155587A patent/KR102649086B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002322063A (en) * | 2001-04-25 | 2002-11-08 | Ito En Ltd | Composition for relieving mental fatigue, composition for maintaining and enhancing concentration power, and composition for maintaining and enhancing mental vitality |
| KR20130000664A (en) * | 2011-06-23 | 2013-01-03 | 농업회사법인 맑은내일 주식회사 | Composition with stimulating effect, comprising the extract of medicinal plants |
| KR102070701B1 (en) * | 2019-05-02 | 2020-01-29 | (주)오르나 | Composition for antioxidant comprising bilberry juice, sea buckthorn juice, lingonberry juice |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102649086B1 (en) | 2024-03-19 |
| KR20230005717A (en) | 2023-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003160505A (en) | Food and drink as well as external preparation with body fat reducing effect | |
| KR101789424B1 (en) | Medicinal-Herb Composition Comprising Chinese matrimony vine Proving Insomniac and the Method of Making the Same | |
| KR20170090618A (en) | A preparation method of jelly and beverage compositions containing Aronia extrac reduced tannin and L-arginine | |
| WO2019146881A1 (en) | Composition for preventing or treating dry eye syndrome, containing aucuba japonica extract | |
| KR20130035091A (en) | Composition for preventing and treating varicocele or male infertility comprising anthocyanin extracted from black soybean | |
| KR101693361B1 (en) | Cudrania tricupspidate drinks comprising cudrania tricupspidate extract and method for manufacturing thereof | |
| KR102328028B1 (en) | Jelly type composition for enhancing concentration | |
| US20080138384A1 (en) | Oral hair growth stimulants comprising orthosiphon | |
| KR20170091545A (en) | Fuctional mashed adzuki beans and method for preparing the functional mashed adzuki beans using germinated adzuki beans | |
| US7399491B2 (en) | Health promoting functional foods fortified with herbs | |
| KR101800802B1 (en) | Method for manufacturing Glycyrrhiza uralensis extract and composition for treating or preventing oral diseases comprising the extract | |
| KR20180052514A (en) | A method for manufacturing low temperature aging garlic and composition for antifatigue comprising there of extract | |
| KR101614431B1 (en) | A pharmaceutical composition for improving generative of male and treating infertility | |
| KR20070033236A (en) | Liver function protectant containing ellagic acid, ellagitannin and natural plant extracts containing the same as active ingredients | |
| KR100496524B1 (en) | Composition for eliminating hangover | |
| KR102649426B1 (en) | Oral spray composition | |
| KR101596006B1 (en) | Composition for Prevention and Treatment of Cardiovascular Diseases | |
| KR20120111648A (en) | A plum beverage composition containing natural fermented plum juice and the manufacturing method thereof | |
| KR102516108B1 (en) | Granule royal jelly composition and method for thereof | |
| RU2537902C2 (en) | Rock candy | |
| KR102061622B1 (en) | Composition including mori folium extracts for antioxidant activation and anti-inflammatory | |
| KR100915457B1 (en) | Functional food comprising microcapsule contained extracts of Viscum album loranthacea | |
| KR101090133B1 (en) | Preparing method of white lotus leaf tea and extract containing GABA and antioxidant effect | |
| KR102025572B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of Diospyros lotus leaf and grape fruit stem extract as effective component | |
| JP2007169204A (en) | Food and drink comprising superoxide scavenger and extract from vaccinium dunalianum var. urophyllum formulated therein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| A107 | Divisional application of patent | ||
| GRNT | Written decision to grant |